Management ChangeMay 28, 2026, 05:04 PM
Allogene Therapeutics Names Zachary Roberts New CEO, Effective July 1
AI Summary
Allogene Therapeutics announced a leadership transition, with Dr. David Chang stepping down as President and Chief Executive Officer on June 30, 2026, after eight years. Dr. Chang, a co-founder, will continue to serve on the Board of Directors. Zachary Roberts, currently Executive Vice President, Research & Development and Chief Medical Officer, has been unanimously elected to succeed Dr. Chang as President and CEO, effective July 1, 2026, and will also join the Board.
Key Highlights
- David Chang to transition from President and CEO on June 30, 2026, after eight years of leadership.
- Dr. Chang will continue to serve on Allogene's Board of Directors.
- Zachary Roberts appointed President and CEO, effective July 1, 2026.
- Dr. Roberts will also be appointed to the Board of Directors on July 1, 2026.
- Dr. Roberts joined Allogene in January 2023 as EVP, Research & Development and Chief Medical Officer.
- Dr. Roberts led the design and execution of the pivotal ALPHA3 trial in 1L consolidation LBCL.
Price Impact
More from ALLO